Stock AnalizCadre Holdings, Inc. CDRE
Industrial Specialties · IPO 2021 · data as of November 13, 2026
Cadre Holdings, Inc. (CDRE) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $733M and net income of $41M, a net margin of 5.6%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is shareholder returns (4/5); the weakest is value (1/5).
Key numbers: a P/E of 36.7, a price to free cash flow of 18.8, 5-year revenue growth of 9% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 43% below the current price.
Score: 2.6 / 5
Checks passed
- P/FCF below 20
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $733M | $610M | $568M | $483M | $458M | $427M | $405M |
| Net income | $41M | $44M | $36M | $39M | $6M | $13M | $38M |
| Free cash flow | $76M | $57M | $26M | $66M | $42M | $37M | $41M |
| EPS (diluted) | $0.91 | $1.02 | $0.90 | $1.02 | $0.16 | $0.44 | $1.40 |
| Net margin | 5.6% | 7.2% | 6.4% | 8.0% | 1.3% | 3.0% | 9.5% |
| ROIC | — | 7.4% | 8.1% | 12.0% | 3.2% | 13.7% | 17.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $46.83, 40% above the current price; targets range from $40.00 to $62.00; the consensus rating is “Strong buy”; expected EPS is $1.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Cadre’s P/E ratio?
About 36.7, based on the last twelve months of diluted earnings per share (forward P/E about 23.2).
Is Cadre stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 43% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cadre pay a dividend?
Yes. The dividend yield is about 1.17%, and it has paid dividends for 5 years in our data.
Is Cadre a good stock to buy?
We do not give buy or sell advice. Cadre scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.